Eyegate pharmaceuticals inc (EYEG)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating Activities:
Net (Loss) Income

-9,919

-7,096

-6,922

-6,618

-7,561

-10,811

-11,114

-12,130

-12,677

-13,217

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,343

-12,332

-10,311

-8,029

-8,387

-6,049

-4,344

-3,449

-1,551

0

0

0

Adjustments to Reconcile Net (Loss) Income to Net Cash Used in Operating Activities:
Depreciation and Amortization of Intangible Assets

45

51

51

48

43

38

31

26

22

19

18

14

9

5

0

0

0

1

1

1

1

1

0

0

0

Reduction of Right-of-Use Assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of Right-of-Use Assets

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-Cash Interest Expense Charge on Beneficial Conversion Feature of Notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,663

-1,663

-1,663

-1,663

0

0

0

0

Non-Cash Interest Expense Related to Debt Discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

244

0

0

0

-

-

-

-

Fair value adjustment on common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Stock-Based Compensation

765

852

903

1,053

962

875

789

649

738

870

821

785

674

510

470

686

853

1,224

1,146

778

488

26

0

0

0

Expiration of Prepaid Agreement

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value Adjustment on Common Stock Warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-223

0

0

0

-

-

-

-

Loss on Cancellation of Stockholder Note Receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in Operating Assets and Liabilities:
License and Grant Receivable

-

-

-

-

-

-

-

-

-

-37

-290

-2,263

-6,591

-3,233

-471

45

337

907

0

0

0

-

-

-

-

Prepaid Expenses and Other Current Assets

-172

3

-341

-268

-238

-379

287

79

151

447

132

183

114

-26

74

132

199

95

68

110

162

4

0

0

0

Refundable Tax Credit Receivable

-1

-13

-12

-10

-17

-4

-3

-4

6

4

5

-9

-7

-7

-6

5

1

2

0

-41

-8

-7

0

0

0

Other Assets

58

37

-58

-78

-78

-69

-19

0

0

1

2

10

8

16

16

7

9

1

0

0

-24

1

0

0

0

Accounts Payable

-86

146

743

-259

22

-642

-334

-614

-1,089

-706

-745

-262

438

712

964

613

304

-148

-117

107

278

552

0

0

0

Lease Liabilities

164

162

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred Revenue

0

-2,686

-2,686

-2,723

-2,053

540

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unbilled Revenue

-

-

-

-

-

689

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred Revenue

-

-

-

-

-

-

-

-

-

-

-

3,980

-798

0

1,955

2,563

2,705

1,907

0

0

0

-

-

-

-

Unbilled Revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued Expenses

-83

10

-158

-299

-826

-694

-571

-120

549

144

704

-154

-57

450

644

891

668

265

-626

-266

-82

896

0

0

0

Net Cash Used in Operating Activities

-8,407

-8,153

-7,570

-8,353

-8,876

-10,844

-10,294

-10,031

-10,564

-6,468

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Investing Activities:
Restricted Cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

25

10

20

0

0

0

-

-

-

-

Net Cash Used in Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,746

-4,043

-4,459

-3,346

-3,207

-2,288

-950

0

0

0

Acquisition of Jade (Net of Cash Acquired)

-

-

-

-

-

-

-

-

-

-

-

-

-

185

185

185

185

0

0

0

0

-

-

-

-

Financing Activities:
Net Cash Provided by Investing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

160

175

-20

0

0

0

-

-

-

-

Proceeds from Initial Public Stock Offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,099

4,099

0

0

0

0

Proceeds from Stock Offerings, Net of Offering Costs

6,279

1,777

0

0

0

-

-

-

-

10,589

10,589

10,589

5,690

3,768

0

0

0

-

-

-

-

-

-

-

-

Proceeds from convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,755

0

0

0

Exercise of Common Stock Options

-

-

-

-

-

-

-

-

-

40

40

40

58

56

64

68

11

26

18

21

21

6

0

0

0

Stock Issuance Costs

-

-

-

-

-

-

-

-

0

-

-

-

422

323

0

0

0

-

-

-

-

-

-

-

-

Offering Costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,479

1,439

901

1,373

1,148

0

0

0

Equipment Financing Payments

3

4

6

6

8

9

11

12

12

12

12

9

6

2

0

0

0

-

-

-

-

-

-

-

-

Net Cash Provided by (Used in) Financing Activities

8,423

3,920

123

476

11,346

11,304

11,245

10,904

8,805

10,671

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of Grants Payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Grant Refund

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net Cash Provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,328

8,759

12,616

12,932

4,009

4,024

613

0

0

0

Effect of Exchange Rate Changes on Cash

-

-

-

-

-

-

-

-

7

4

11

8

6

6

14

9

38

90

42

89

46

3

0

0

0

Effect of Exchange Rate Changes on Cash

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Increase (Decrease) in Cash

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Decrease in Cash

-

-

-

-

-

-

-

-

-1,789

4,170

3,587

3,761

-1,752

-4,733

-4,237

6,752

4,929

8,227

9,608

872

1,761

-334

0

0

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental Disclosures of Noncash Operating and Financing Activities
Creation of Right-of-Use Assets and Related Lease Liabilities

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Non-Controlling Interests to Common Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,818

6,818

6,818

6,818

0

0

0

0

Creation of Right-of-Use Assets and Related Lease Liabilities

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

36,408

36,408

36,408

36,408

0

0

0

0

Cancellation of Restricted Stock

0

0

-35

35

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant of Restricted Stock Awards

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of Common Warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

Conversion of Promissory Notes and Accrued Interest into Common Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,532

3,532

3,532

3,532

0

0

0

0

Deemed Dividend on Conversion of Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,222

0

0

0

-

-

-

-

Application of Deferred Offering Costs on IPO

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,148

0

0

0

-

-

-

-

Warrant Liability Reclassified to Stockholders Equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

79

0

0

0

-

-

-

-

Issuance of Common Stock to Acquire Jade Therapeutics, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

2,909

2,909

2,470

2,442

0

0

0

0

-

-

-

-

Contingent Liability in Connection with Jade Acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

1,210

1,210

1,210

1,210

0

0

0

0

-

-

-

-

ASU 2016-02
Creation of Right-of-Use Assets and Related Lease Liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-